Form D — ABLi Therapeutics, Inc.
0002104142-26-000001 · filed Jan 13, 2026
Figures are issuer-reported and describe stored filings. Data coverage and methodology.
Check this disclosure on SEC EDGAR · More Pharmaceuticals filings
Offering
- Industry
- Pharmaceuticals
- Exemptions
- Rule 506(b)
- Reported offering amount
- $1,000,000
- Reported amount sold
- $1,000,000
- Minimum investment
- $0
- Investors
- —
- Sales commission
- —
- Finders' fees
- —
Issuer
- Name
- ABLi Therapeutics, Inc.
- CIK
- 2104142
- Entity
- Corporation
- Jurisdiction
- DELAWARE
- Year incorporated
- 2025
- Address
- 3350 RIVERWOOD PKWY SE
ATLANTA, Georgia 30339 - Phone
- 917-494-0831
Related persons
May not be accurate — issuers self-report this list and the SEC does not verify it. Cross-check the original SEC EDGAR filing if accuracy matters.
-
Milton H. Werner · Executive OfficerAtlanta, Georgia Find on LinkedIn ↗
-
Garth Lees-Rolfe · Executive OfficerAtlanta, Georgia Find on LinkedIn ↗
-
Anastasia Daifotis · DirectorAtlanta, Georgia Find on LinkedIn ↗
-
Jeffrey Young · DirectorAtlanta, Georgia Find on LinkedIn ↗
View the original filing on SEC EDGAR ↗